Funder: National Institutes of Health
Due Dates: November 5, 2026 (Resubmission) | February 5, 2027 (New) | March 5, 2027 (Resubmission) | June 5, 2027 (New) | July 5, 2027 (Resubmission) | October 5, 2027 (New) | November 5, 2027 (Resubmission) | January 7, 2028 (Closing)
Funding Amounts: No budget cap; requests must reflect project needs; maximum project period of 5 years; no cost sharing required.
Summary: Supports mechanistic, translational, and clinical research to characterize, prevent, or reduce chronic and delayed adverse effects of cancer therapies.
Key Information: Only new and resubmission applications are accepted; clinical trials are optional.
Description
The National Cancer Institute (NCI), part of NIH, supports R01 research on cancer therapy-induced adverse effects that persist as chronic comorbidities or emerge after treatment. Projects may identify underlying mechanisms, characterize clinical phenotypes, or translate mechanistic understanding into prevention and mitigation strategies. Research may involve adult or pediatric populations in basic science or clinical settings.
The program emphasizes mechanistic studies with translational endpoints and longitudinal clinical phenotyping. Relevant endpoints include biomarkers, imaging, patient-reported outcomes, or combinations suitable for future intervention trials. Research interests include adverse-effect trajectories, objective measures, risk factors, treatment–tumor interactions, and improved risk stratification and detection. Projects coupling mechanistic knowledge with clinical phenotypes receive priority. Clinical–basic science collaborations, understudied and underserved cancer populations, and emerging treatments are encouraged; human-tissue or human-derived-cell validation of preclinical findings is highly recommended.
